Antibiotics, Antitubercular
"Antibiotics, Antitubercular" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic.
MeSH Number(s)
D27.505.954.122.085.089
D27.505.954.122.085.255.135
Below are MeSH descriptors whose meaning is more general than "Antibiotics, Antitubercular".
Below are MeSH descriptors whose meaning is more specific than "Antibiotics, Antitubercular".
This graph shows the total number of publications written about "Antibiotics, Antitubercular" by people in Harvard Catalyst Profiles by year, and whether "Antibiotics, Antitubercular" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 3 | 0 | 3 |
| 2001 | 1 | 3 | 4 |
| 2002 | 2 | 1 | 3 |
| 2003 | 0 | 2 | 2 |
| 2004 | 2 | 1 | 3 |
| 2005 | 2 | 0 | 2 |
| 2006 | 0 | 3 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 3 | 4 |
| 2013 | 1 | 4 | 5 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 1 | 3 |
| 2019 | 3 | 4 | 7 |
| 2020 | 1 | 1 | 2 |
| 2021 | 6 | 0 | 6 |
| 2022 | 2 | 0 | 2 |
Below are the most recent publications written about "Antibiotics, Antitubercular" by people in Profiles.
-
Tuberculosis treatment failure associated with evolution of antibiotic resilience. Science. 2022 12 09; 378(6624):1111-1118.
-
Tuberculosis Pathways to Care and Transmission of Multidrug Resistance in India. Am J Respir Crit Care Med. 2022 01 15; 205(2):233-241.
-
Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19. Int J Tuberc Lung Dis. 2021 09 01; 25(9):772-775.
-
Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV. Cochrane Database Syst Rev. 2021 08 20; 8:CD014641.
-
Xpert Ultra Assay on Stool to Diagnose Pulmonary Tuberculosis in Children. Clin Infect Dis. 2021 07 15; 73(2):226-234.
-
A home-based care programme for rifampicin-resistant TB. Int J Tuberc Lung Dis. 2021 07 01; 25(7):587-589.
-
Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis. Cochrane Database Syst Rev. 2021 05 06; 5:CD012972.
-
Reply to: "Human rights: finding the right balance for rifampicin-resistant TB treatment". Int J Tuberc Lung Dis. 2021 04 01; 25(4):328-329.
-
Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms. Cochrane Database Syst Rev. 2021 03 23; 3:CD013694.
-
Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database Syst Rev. 2021 02 22; 2:CD009593.